NO news is not necessarily good news in cancer

Current Cancer Drug Targets

Volumn 5, Issue 2, 2005, Pages 103-115

  Ekmekcioglu, Suhendan ^a   Tang, Chi Hui ^b   Grimm, Elizabeth A ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cancer; Chemotherapy; Drug resistance; Nitric oxide; NOS; Prognostic markers

Indexed keywords

CISPLATIN; FLAVOPIRIDOL; INDUCIBLE NITRIC OXIDE SYNTHASE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE INHIBITOR; PROTEIN P53; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN METABOLITE;

ANGIOGENESIS; CANCER; CANCER CELL; CANCER GROWTH; CANCER INVASION; CANCER SURVIVAL; CARCINOGENESIS; CELL FUNCTION; DIATOM; DRUG TARGETING; HUMAN; HUMAN CELL; IMMUNOSURVEILLANCE; MELANOMA; METASTASIS; OXIDATIVE STRESS; REVIEW; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

ANIMALS; ANTINEOPLASTIC AGENTS; ENZYME INHIBITORS; HUMANS; NEOPLASMS; NITRIC OXIDE; NITRIC OXIDE SYNTHASE;

EID: 16844368414     PISSN: 15680096     EISSN: None     Source Type: Journal    
DOI: 10.2174/1568009053202072     Document Type: Review

References (139)

1. Knowles, R. G.; Moncada, S. Nitric oxide synthases in mammals. Biochem. J. 1994, 298(Pt 2), 249-258.
2. Marietta, M. A. Nitric oxide synthase: aspects concerning structure and catalysis. Cell 1994, 78, 927-930.
3. Nathan, C.; Xie, Q. W. Nitric oxide synthases: roles, tolls, and controls. Cell 1994, 78, 915-918.
4. Hall, A. V.; Antoniou, H.; Wang, Y.; Cheung, A. H.; Arbus, A. M.; Olson, S. L.; Lu, W. C.; Kau, C. L.; Marsden, P. A. Structural organization of the human neuronal nitric oxide synthase gene (NOS1). J. Biol. Chem. 1994, 269, 33082-33090.
5. Alderton, W. K.; Cooper, C. E.; Knowles, R. G. Nitric oxide synthases: structure, function and inhibition. Biochem. J. 2001, 357, 593-615.
6. Charles, I. G.; Palmer, R. M. J.; Hickery, M. S.; Bayliss, M. T.; Chubb, A. P.; Hall, V. S.; Moss, D. W.; Moncada, S. Cloning, Characterization, and and expressions of a cDNA endocing an inducible nitric oxide synthase from the human chondrocyte. Proc. Natl. Acad. Sci. USA 1993, 90, 11419-11423.
7. Janssens, S. P.; Shimouchi, A.; Quertermous, T.; Bloch, D. B.; Bloch, K. D. Cloning and expression of a cDNA encoding human endothelium-derived relaxing factor/nitric oxide synthase. J. Biol. Chem. 1992, 267, 14519-14522. [Published Erratum Appears in J. Biol. Chem. 1992, 267, 22694].
8. Janssens, S. P.; Shimouchi, A.; Quertermous, T.; Bloch, D. B.; Bloch, K. D. Cloning and expression of a cDNA encoding human endothelium-derived relaxing factor/nitric oxide synthase. J. Biol. Chem. 1992, 267, 14519-14522. [Published Erratum Appears in J. Biol. Chem. 1992, 267, 22694].
9. Marsden, P. A.; Schappert, K. T.; Chen, H. S.; Flowers, M.; Sundell, C. L.; Wilcox, J. N.; Lamas, S.; Michel, T. Molecular cloning and characterization of human endothelial nitric oxide synthase. FEBS Lett. 1992, 307, 287-293.
10. Thomsen, L. L.; Lawton, F. G.; Knowles, R. G.; Beesley, J. E.; Riveros-Moreno, V.; Moncada, S. Nitric oxide synthase activity in human gynecological cancer. Cancer Res. 1994, 54, 1352-1354.
11. Thomsen, L. L.; Miles, D. W.; Happerfield, L.; Bobrow, L. G.; Knowles, R. G.; Moncada, S. Nitric oxide synthase activity in human breast cancer. Br. J. Cancer 1995, 72, 41-44.
12. Cobbs, C. S.; Brenman, J. E.; Aldape, K. D.; Bredt, D. S.; Israel, M. A. Expression of nitric oxide synthase in human central nervous system tumors. Cancer Res. 1995, 55, 727-730.
13. Tschugguel, W.; Pustelnik, T.; Lass, H.; Mildner, M.; Weninger, W.; Schneeberger, C.; Jansen, B.; Tschachler, E.; Waldhor, T.; Huber, J. C.; Pehamberger, H. Inducible nitric oxide synthase (inos) expression may predict distant metastasis in human melanoma [Published Erratum Appears in Br. J. Cancer 1999, 50(8), 1302], Br. J. Cancer 1999, 79, 1609-1612.
14. Tschugguel, W.; Pustelnik, T.; Lass, H.; Mildner, M.; Weninger, W,; Schneeberger, C.; Jansen, B.; Tschachler, E.; Waldhor, T.; Huber, J. C.; Pehamberger, H. Inducible nitric oxide synthase (inos) expression may predict distant metastasis in human melanoma [Published Erratum Appears in Br. J. Cancer 1999, 50(8), 1302], Br. J. Cancer 1999, 79, 1609-1612.
15. Koh, E.; Non, S. H.; Lee, Y. D.; Lee, H. Y.; Man, J. W.; Lee, H. W.; Hong, S. Differential expression of nitric oxide synthase in human stomach cancer. Cancer Lett. 1999, 146, 173-180.
16. Baltaci, S.; Orhan, D.; Gogus, C.; Turkolmez, K.; Tulunay, O.; Gogus, O. Inducible nitric oxide synthase expression in benign prostatic hyperplasia, low- and high-grade prostatic intraepithelial neoplasia and prostatic carcinoma. BJU International 2001, 88, 100-103.
17. Vakkala, M.; Kahlos, K.; Lakari, E.; Paakko, P.; Kinnula, V.; Soini, Y. Inducible nitric oxide synthase expression, apoptosis, and angiogenesis in in situ and invasive breast carcinomas. Clin. Cancer Res. 2000, 6, 2408-2416.
18. Ekmekcioglu, S.; Ellerhorst, J.; Smid, C. M.; Prieto, V. G.; Munsell, M.; Buzaid, A. C.; Grimm, E. A. Inducible nitric oxide synthase and nitrotyrosine in human metastatic melanoma tumors correlate with poor survival. Clin. Cancer Res. 2000, 6, 4768-4775.
19. Tschugguel, W.; Schneeberger, C.; Unfried, G.; Czerwenka, K.; Weninger, W.; Mildner, M.; Gruber, D. M.; Sator, M. O.; Waldhor, T.; Huber, J. C. Expression of inducible nitric oxide synthase in human breast cancer depends on tumor grade. Breast Cancer Res. Treat. 1999, 56, 143-149.
20. Cobbs, C. S.; Brenman, J. E., Aldape, K. D.; Bredt, D. S.; Israel, M. A. Expression of nitric oxide synthase in human central nervous system tumors. Cancer Res. 1995, 55, 727-730.
21. Ekmekcioglu, S.; Ellerhorst, J. A.; Mumm, J. B.; Zheng, M.; Broemeling, L.; Prieto, V. G.; Stewart, A. L.; Mhashilkar, A. M.; Chada, S.; Grimm, E. A. Negative association of melanoma differentiation-associated gene (Mda-7) and inducible nitric oxide synthase (INOS) in human melanoma: MDA-7 regulates INOS expression in melanoma cells. Mol. Cancer Ther. 2003, 2, 9-17.
22. Ekmekcioglu, S.; Ellerhorst, J.; Mhashilkar, A. M.; Sahin, A. A.; Read, C. M.; Prieto, V. G.; Chada, S.; Grimm, E. A. Down-regulated melanoma differentiation associated gene (Mda-7) expression in human melanomas. Intl. J. Cancer 2001, 94, 54-59.
23. Ellerhorst, J. A.; Prieto, V. G.; Ekmekcioglu, S.; Broemeling, L.; Yekell, S.; Chada, S.; Grimm, E. A. Loss of MDA-7 expression with progression of melanoma. J. Clin. Oncol. 2002, 20, 1069-1074.
24. Reveneau, S.; Arnould, L.; Jolimoy, G., Hilpert, S.; Lejeune, P.; Saint-Giorgio, V.; Belichard, C.; Jeannin, J. F. Nitric oxide synthase in human breast cancer is associated with tumor grade, proliferation rate, and expression of progesterone receptors. Lab. Invest. 1999, 79, 1215-1225.
25. Loibl, S.; von Minckwitz, G.; Weber, S.; Sinn, H. P.; Schini-Kerth, V. B.; Lobysheva, I.; Nepveu, F.; Wolf, G.; Strebhardt, K.; Kaufmann, M. Expression of endothelial and inducible nitric oxide synthase in benign and malignant lesions of the breast and measurement of nitric oxide using electron paramagnetic resonance spectroscopy. Cancer 2002, 95, 1191-1198.
26. Jenkins, D. C.; Charles, I. G.; Thomsen, L. L.; Moss, D. W.; Holmes, L. S.; Baylis, S. A.; Rhodes, P.; Westmore, K.; Emson, P. C.; Moncada, S. Roles of Nitric oxide in tumor growth. Proc. Natl. Acad. Sci. USA 1995, 92, 4392-4396.
27. Haendeler, J.; Weiland, U.; Zeiher, A. M.; Dimmeler, S. effects of redox-related congeners of NO on apoptosis and caspase-3 activity. Nitric Oxide 1997, 1, 282-293.
28. Ahmed, B.; Van Den Oord, J. J. Expression of the inducible isoform of nitric oxide synthase in pigment cell lesions of the skin. Br. J. Dermatol. 2000, 142, 432-440.
29. Salvucci, O.; Carsana, M.; Bersani, I.; Tragni, G.; Anichini, A. Antiapoptotic role of endogenous nitric oxide in human melanoma cells. Cancer Res. 2001, 61, 318-326.
30. Oshima, H.; Bartsch, H. chronic infections and inflammatory processes as cancer risk factors: possible role of nitric oxide in carcinogenesis. Mutat. Res. 1994, 305, 253-264.
31. Singer, I. I.; Kawka, D. W.; Scott, S.; Weidner, J. R.; Mumford, R. A.; Riehl, T. E.; Stenson, W. F. Expression of inducible nitric oxide synthase and nitrotyrosine in colonic epithelium in inflammatory bowel disease. Gastroenterology 1996, 111, 871-885.
32. Mannick, E. E.; Bravo, L. E.; Zarania, G.; Realpe, J. L.; Zhang, X. J.; Ruiz, B.; Fontham, E. T.; Mera, R.; Miller, M. J.; Correa, P. Inducible nitric oxide synthase, nitrotyrosine, and apoptosis in Helicobacter pylori gastritis: effect of antibiotics and antioxidants. Cancer Res. 1996, 56, 3238-3243.
33. Ziehe, M.; Morbidelli, L.; Choudhuri, R.; Zhang, H. T.; Donnini, S.; Granger, H. J.; Bicknell, R. Nitric oxide synthase lies downstream from vascular endothelial growth factor-induced but not basic fibroblast growth factor-induced angiogenesis. J. Clin. Invest. 1997, 99, 2625-2634.
34. Zhao, H.; Dugas, N.; Mathiot, C.; Delmer, A.; Dugas, B.; Sigaux, F.; Kolb, J. P. B-Cell chronic lymphocytic leukemia cells express a functional inducible nitric oxide synthase displaying anti-apoptotic activity. Blood 1998, 92, 1031-1043.
35. Cow, A. J.; Farkouh, C. R.; Munson, D. A.; Posencheg, M. A.; Ischiropoulos, H. Biological significance of nitric oxide-mediated protein modifications. Am. J. Physiol. Lung Cell Mol. Physiol. 2004, 257, L262-L268.
36. Pryor, W. A.; Squadrito, G. L. The chemistry of peroxynitrite: a product from the reaction of nitric oxide with superoxide. Am. J. Physiol. 1995, 268, L699-L722.
37. Schmidt, H. H. H. W. NO-, CO and -OH endogenous soluble guanylyl cyclase-activating factors. FEBS Lett. 1992, 307, 102-107.
38. Go, Y. M.; Patel, R. P.; Maland, M. C.; Park, H.; Beckman, J. S.; Darley-Usmar, V. M.; Jo, H. Evidence for peroxynitrite as a signaling molecule in flow-dependent activation of C-Jun NH(2)-terminal kinase. Am. J. Physiol. 1999, 277, H1647-H1653.
39. Lander, H. M.; Sehajpal, P.; Levine, D. M.; Novogrodsky, A. Activation of human peripheral blood mononuclear cells by nitric oxide-generating compounds. J. Immunol. 1993, 150, 1509-1516.
40. Lander, H. M.; Jacovina, A. T.; Davis, R. J.; Tauras, J. M. Differential activation of mitogen-activated protein kinases by nitric oxide-related species. J. Biol Chem. 1996, 271, 19705-19709.
41. Lander, H. M.; Ogiste, J. S.; Pearce, S. F.; Levi, R.; Novogrodsky, A. Nitric oxide-stimulated guanine nucleotide exchange on p21ras. J. Biol. Chem. 1995, 270, 7017-7020.
42. MacMillan-Crow, L. A.; Greendorfer, J. S.; Vickers, S. M.; Thompson, J. A. Tyrosine nitration of c-src tyrosine kinase in human pancreatic ductal adenocarcinoma. Arch. Biochem. Biophys. 2000, 377, 350-356.
43. Akhand, A. A.; Pu, M.; Senga, T.; Kato, M.; Suzuki, H.; Miyata, T.; Hamaguchi, M.; Nakashima, I. Nitric oxide controls src kinase activity through a sulfhydryl group modification-mediated Tyr-527-independent and Tyr-416-linked mechanism. J. Biol. Chem. 1999, 274, 25821-25826.
44. Nikitovic, D.; Holmgren, A.; Spyrou, G. Inhibition of AP-1 DNA binding by nitric oxide involving conserved cysteine residues in Jun and Fos. Biochem. Biophys. Res. Commun. 1998, 242, 109-112.
45. Beck, K. F.; Eberhardt, W.; Frank, S.; Huwiler, A.; Messmer, U. K.; Muhl, H.; Pfeilschifter, J. Inducible NO synthase: role in cellular signalling. J. Exp. Biol. 1999, 202, 645-653.
46. Duhe, R. J.; Evans, G. A.; Erwin, R. A.; Kirken, R. A.; Cox, G. W.; Farrar, W. L. Nitric oxide and thiol redox regulation of Janus kinase activity. Proc. Natl. Acad. Sci. USA 1998, 95, 126-131.
47. Korkmaz, Y.; Baumann, M. A.; Schroder, H.; Behrends, S.; Addicks, K.; Raab, W. H.; Bloch, W. Localization of the NO-cGMP signaling pathway molecules, NOS III-phosphorylation sites, ERK1/2, and Akt/PKB in osteoclasts. J. Periodontol. 2004, 75, 1119-1125.
48. Huang, H. N.; Lu, P. J.; Lo, W. C.; Lin, C. H.; Hsiao, M.; Tseng, C. J. In situ Akt phosphorylation in the nucleus tractus solitarii is involved in central control of blood pressure and heart rate. Circulation 2004, 110, 2476-2483.
49. Wang, Y.; Ahmad, N.; Kudo, M.; Ashraf, M. Contribution of Akt and endothelial nitric oxide synthase to diazoxide-induced late preconditioning. Am. J. Physiol. Heart Circ. Physiol. 2004, 287, H1125-H1131.
50. Mondoro, T. H.; Shafer, B. C.; Vostal, J. G. Peroxynitrite-induced tyrosine nitration and phosphorylation in human platelets. Free Radic. Biol. Med. 1997, 22, 1055-1063.
51. Souza, J. M.; Daikhin, E.; Yudkoff, M.; Raman, C. S.; Ischiropoulos, H. Factors determining the selectivity of protein tyrosine nitration. Arch. Biochem. Biophys. 1999, 371, 169-178.
52. Davies, H.; Bignell, G. R.; Cox, C.; Stephens, P.; Edkins, S.; Clegg, S.; Teague, J.; Woffendin, H.; Garnett, M. J.; Bottomley, W.; Davis, N.; Dicks, E.; Ewing, R.; Floyd, Y.; Gray, K.; Hall, S.; Hawes, R.; Hughes, J.; Kosmidou, V.; Menzies, A.; Mould, C.; Parker, A.; Stevens, C.; Watt, S.; Hooper, S.; Wilson, R.; Jayatilake, H.; Gusterson, B. A.; Cooper, C.; Shipley, J.; Hargrave, D.; Pritchard-Jones, K.; Maitland, N.; Chenevix-Trench, G.; Riggins, G. J.; Bigner, D. D.; Palmieri, G.; Cossu, A.; Flanagan, A.; Nicholson, A.; Ho, J. W.; Leung, S. Y.; Yuen, S. T.; Weber, B. L.; Seigler, H. F.; Darrow, T. L.; Paterson, H.; Marais, R.; Marshall, C. J.; Wooster, R.; Stratton, M. R.; Futreal, P. A. Mutations of the BRAF gene in human cancer. Nature 2002, 417, 949-954.
53. Brose, M. S.; Volpe, P.; Feldman, M.; Kumar, M.; Rishi, I.; Gerrero, R.; Einhorn, E.; Herlyn, M.; Minna, J.; Nicholson, A.; Roth, J. A.; Albelda, S. M.; Davies, H.; Cox, C.; Brignell, G.; Stephens, P.; Futreal, P. A.; Wooster, R.; Stratton, M. R.; Weber, B. L. BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res. 2002, 62, 6997-7000.
54. Yu, D. The role of oncogenes in drug resistance. Cytotechnology 1998, 27, 283-292.
55. Grossman, D.; Altieri, D. C. Drug resistance in melanoma: mechanisms, apoptosis, and new potential therapeutic targets. Cancer Metast. Rev. 2001, 20, 3-11.
56. Serrone, L.; Hersey, P. The Chemoresistance of Human Malignant Melanoma: an Update. Melanoma Res. 1999, 9, 51-58.
57. Soengas, M. S.; Lowe, S. W. Apoptosis and melanoma Chemoresistance. Oncogene 2003, 22, 3138-3151.
58. Soengas, M. S.; Capodieci, P.; Polsky, D.; Mora, J.; Esteller, M.; Opitz-Araya, X.; McCombie, R.; Herman, J. G.; Gerald, W. L.; Lazebnik, Y. A.; Cordon-Cardo, C.; Lowe, S. W. Inactivation of the apoptosis effector Apaf-1 in malignant melanoma. Nature 2001, 409, 207-211.
59. Melino, G.; Bernassola, F.; Knight, R. A.; Corasaniti, M. T.; Nistico, G.; Finazzi-Agro, A. S-Nitrosylation regulates apoptosis. Nature 1997, 388, 432-433.
60. Torok, N. J.; Higuchi, H.; Bronk, S.; Gores, G. J. Nitric oxide inhibits apoptosis downstream of cytochrome c release by nitrosylating caspase 9. Cancer Res. 2002, 62, 1648-1653.
61. Rossig, L.; Fichtischerer, B.; Breitschopf, K.; Haendeler, J.; Zeiher, A. M.; Mulsch, A.; Dimmeler, S. Nitric oxide inhibits caspase-3 by s-nitrosation in vivo. J. Biol. Chem. 1999, 274, 6823-6826.
62. Li, J.; Billiar, T. R.; Talanian, R. V.; Kim, Y. M. Nitric oxide reversibly inhibits seven members of the caspase family via s-nitrosylation. Biochem. Biophys. Res. Commun. 1997, 240, 419-424.
63. Mannick, J. B.; Miao, X. Q.; Stamler, J. S. Nitric oxide inhibits Fas-induced apoptosis. J. Biol. Chem. 1997, 272, 24125-24128.
64. Mannick, J. B.; Hausladen, A.; Liu, L.; Hess, D. T.; Zeng, M.; Miao, Q. X.; Kane, L. S.; Gow, A. J.; Stamler, J. S. Fas-induced caspase denitrosylation. Science 1999, 284, 651-654.
65. Jaiswal, M.; LaRusso, N. F.; Gores, G. J. Nitric oxide in gastrointestinal epithelial cell carcinogenesis: linking inflammation to oncogenesis. Am. J. Physiol. Gastrointest. Liver Physiol. 2001, 257, G626-G634.
66. Kim, Y. M.; de Vera, M. E.; Watkins, S. C.; Billiar, T. R. Nitric oxide protects cultured rat hepatocytes from tumor necrosis factor-alpha-induced apoptosis by inducing heat shock protein 70 expression. J. Biol. Chem. 1997, 272, 1402-1411.
67. Suschek, C. V.; Krischel, V.; Bruch-Gerharz, D.; Berendji, D.; Krutmann, J.; Kroncke, K. D.; Kolb-Bachofen, V. Nitric oxide fully protects against uva-induced apoptosis in tight correlation with Bcl-2 up-regulation. J. Biol. Chem. 1999, 274, 6130-6137.
68. Li, G.; Tang, L.; Zhou, X.; Tron, V.; Ho, V. Chemotherapy-induced apoptosis in melanoma cells is p53 dependent. Melanoma Res. 1998, 8, 17-23.
69. Davol, P. A.; Goulette, F. A.; Frackelton, A. R. Jr.; Darnowski, J. W. Modulation of p53 expression by human recombinant interferon-alpha2a correlates with abrogation of cisplatin resistance in a human melanoma cell line. Cancer Res. 1996, 56, 2522-2526.
70. Bunz, F.; Hvvang, P. M.; Torrance, C.; Waldman, T.; Zhang, Y.; Dillehay, L.; Williams, J.; Lengauer, C.; Kinzler, K. W.; Vogelstein, B. Disruption of p53 in human cancer cells alters the responses to therapeutic agents. J. Clin. Invest. 1999, 104, 263-269.
71. Davis, D. W.; Weidner, D. A.; Holian, A.; McConkey, D. J. Nitric oxide-dependent activation of p53 suppresses bleomycin-induced apoptosis in the lung. J. Exp. Med. 2000, 192, 857-869.
72. Tang, C. H.; Grimm, E. A. Depletion of endogenous nitric oxide enhances cisplatin-induced apoptosis in a p53-dependent manner in melanoma cell lines. J. Biol. Chem. 2004, 279, 288-298.
73. Schonhoff, C. M.; Daou, M. C.; Jones, S. N.; Schiffer, C. A., Ross, A. H. Nitric oxide-mediated inhibition of hdm2-p53 binding. Biochemistry 2002, 41, 13570-13574.
74. Ashcroft, M.; Vousden, K. H. Regulation of p53 stability. Oncogene 1999, 18, 7637-7643.
75. Zhang, Y.; Xiong, Y. Control of p53 ubiquitination and nuclear export by MDM2 and ARF. Cell Growth Differ. 2001, 12, 175-186.
76. Poremba, C.; Yandell, D. W.; Metze, D.; Kamanabrou, D.; Bocker, W.; Dockhorn-Dworniczak, B. Immunohistochemical detection of p53 in melanomas with rare p53 gene mutations is associated with Mdm-2 overexpression. Oncol. Res. 1995, 7, 331-339.
77. Li, J.; Billiar, T. R. The anti-apoptotic actions of nitric oxide in hepatocytes. Cell Death Differ. 1999, 6, 952-955.
78. Szabo, C. Multiple pathways of peroxynitrite cytotoxicity. Toxicol. Lett. 2003, 140-141, 105-112.
79. Janssen, Y. M.; Soultanakis, R.; Steece, K.; Heerdt, E.; Singh, R. J.; Joseph, J.; Kalyanaraman, B. Depletion of nitric oxide causes cell cycle alterations, apoptosis, and oxidative stress in pulmonary cells. Am. J. Physiol. 1998, 275, L1100-L1109.
80. Wenzel, U.; Kuntz, S.; De Sousa, U. J.; Daniel, H. Nitric oxide suppresses apoptosis in human colon cancer cells by scavenging mitochondrial superoxide anions. Int. J. Cancer 2003, 106, 666-675.
81. Espey, M. G.; Thomas, D. D.; Miranda, K. M.; Wink, D. A. Focusing of nitric oxide mediated nitrosation and oxidative nitrosylation as a consequence of reaction with superoxide. Proc. Natl. Acad. Sci. USA 2002, 99, 11127-11132.
82. Sander, C. S.; Hamm, F.; Elsner, P.; Thiele, J. J. Oxidative stress in malignant melanoma and non-melanoma skin cancer. Br. J. Dermatol. 2003, 148, 913-922.
83. Bittinger, F.; Gonzalez-Garcia, J. L.; Klein, C. L.; Brochhausen, C.; Offner, F.; Kirkpatrick, C. J. Production of superoxide by human malignant melanoma cells. Melanoma Res. 1998, 8, 381-387.
84. Meyskens, F. L. Jr.; Chau, H. V.; Tohidian, N.; Buckmeier, J. Luminol-enhanced chemiluminescent response of human melanocytes and melanoma cells to hydrogen peroxide stress. Pigment Cell Res. 1997, 10, 184-189.
85. Marshall, H. E.; Merchant, K.; Stamler, J. S. Nitrosation and oxidation in the regulation of gene expression. FASEB J. 2000, 14, 1889-1900.
86. Stamler, J. S.; Toone, E. J.; Lipton, S. A.; Sucher, N. J. (S)NO Signals: translocation, regulation, and a consensus motif. Neuron 1997, 18, 691-696.
87. Alderton, W. K.; Cooper, C. E.; Knowles, R. G. Nitric oxide synthases: structure, function and inhibition. Biochem. J. 2001, 357, 593-615.
88. Lala, P. K.; Chakraborty, C. Role of nitric oxide in carcinogenesis and tumour progression. Lancet Oncol. 2001, 2, 149-156.
89. Wink, D. A.; Vodovotz, Y.; Laval, J.; Laval, F.; Dewhirst, M. W.; Mitchell, J. B. The multifaceted roles of nitric oxide in cancer. Carcinogenesis 1998, 19, 711-721.
90. Hogg, N.; Kalyanaraman, B. Nitric oxide and lipid peroxidation. Biochim. Biophys. Acta 1999, 1411, 378-384.
91. Xu, W.; Liu, L.; Smith, G. C.; Charles, G. Nitric oxide upregulates expression of DNA-PKcs to protect cells from DNA-damaging anti-tumour agents. Nat. Cell Biol. 2000, 2, 339-345.
92. Jaiswal, M.; LaRusso, N. F.; Burgart, L. J.; Gores, G. J. Inflammatory cytokines induce DNA damage and inhibit DNA repair in cholangiocarcinoma cells by a nitric oxide-dependent mechanism. Cancer Res. 2000, 60, 184-190.
93. Josko, J.; Mazurek, M. Transcription factors having impact on vascular endothelial growth factor (VEGF) gene expression in angiogenesis. Med. Sci. Monit. 2004, 10, RA89-RA98.
94. Fam, N. P.; Verma, S.; Kutryk, M.; Stewart, D. J. Clinician guide to angiogenesis. Circulation 2003, 108, 2613-2618.
95. Yancopoulos, G. D.; Davis, S.; Gale, N. W.; Rudge, J. S.; Wiegand, S. J.; Holash, J. Vascular-specific growth factors and blood vessel formation. Nature 2000, 407, 242-248.
96. Kashani-Sabet, M.; Sagebiel, R. W.; Ferreira, C. M.; Nosrati, M.; Miller, J. R. III. Tumor vascularity in the prognostic assessment of primary cutaneous melanoma. J. Clin. Oncol. 2002, 20, 1826-1831.
97. Ugurel, S.; Rappl, G.; Tilgen, W.; Reinhold, U. Increased serum concentration of angiogenic factors in malignant melanoma patients correlates with tumor progression and survival. J. Clin. Oncol. 2001, 79, 577-583.
98. Hood, J. D.; Meininger, C. J.; Ziche, M.; Granger, H. J. VEGF upregulates ecNOS message, protein, and NO production in human endothelial cells. Am. J. Physiol. 1998, 274, H1054-H1058.
99. Cooke, J. P. NO and angiogenesis. Atheroscler. Suppl. 2003, 4, 53-60.
100. Urbich, C.; Dernbach, E.; Zeiher, A. M.; Dimmeler, S. Double-edged role of statins in angiogenesis signaling. Circulation Res. 2002, 90, 737-744.
101. Brouet, A.; Sonveaux, P.; Dessy, C.; Moniotte, S.; Balligand, J. L.; Feron, O. Hsp90 and caveolin are key targets for the proangiogenic nitric oxide-mediated effects of statins. Circulation Res. 2001, 59, 866-873.
102. Kureishi, Y.; Luo, Z.; Shiojima, I.; Bialik, A.; Fulton, D.; Lefer, D. J.; Sessa, W. C.; Walsh, K. The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat. Med. 2000, 6, 1004-1010.
103. Wolfrum, S.; Jensen, K. S.; Liao, J. K. Endothelium-dependent effects of statins. Arterioscler. Thromb. Vasc. Biol. 2003, 23, 729-736.
104. Ambs, S.; Merriam, W. G.; Ogunfusika, M. O.; Bennett, W. P.; Ishibe, N.; Hussain, S. P.; Tzeng, E. E.; Geller, D. A.; Billiar, T. R.; Harris, C. C. p53 and vascular endothelial growth factor regulate tumor growth of NOS2-expressing human carcinoma cells. Nat. Med. 1998, 4, 1371-1376.
105. Orucevic, A.; Bechberger, J.; Green, A. M.; Shapiro, R. A.; Billiar, T. R.; Lala, P. K. Nitric-oxide production by murine mammary adenocarcinoma cells promotes tumor-cell invasiveness. Int. J. Cancer 1999, 81, 889-896.
106. Wang, B.; Shi, Q.; Abbruzzese, J. L.; Xiong, Q.; Le, X.; Xie, K. A novel, clinically relevant animal model of metastatic pancreatic adenocarcinoma biology and therapy. Int. J. Pancreatol. 2001, 29, 37-46.
107. Hibbs, J. B. J.; Westenfelder, C.; Taintor, R.; Vavrin, Z.; Kablitz, C.; Baranowski, R. L.; Ward, J. H.; Menlove, R. L.; McMurry, M. P.; Kushner, J. P. Evidence for cytokine-inducible nitric oxide synthesis from 1-arginine in patients receiving interleukin-2 therapy. J. Clin. Invest. 1992, 89, 867-877. [Published Erratum Appears in J. Clin. Invest. 1992, 90, 295].
108. Hibbs, J. B. J.; Westenfelder, C.; Taintor, R.; Vavrin, Z.; Kablitz, C.; Baranowski, R. L.; Ward, J. H.; Menlove, R. L.; McMurry, M. P.; Kushner, J. P. Evidence for cytokine-inducible nitric oxide synthesis from 1-arginine in patients receiving interleukin-2 therapy. J. Clin. Invest. 1992, 89, 867-877. [Published Erratum Appears in J. Clin. Invest. 1992, 90, 295].
109. Citterio, G.; Pellegatta, F.; Lucca, G. D.; Fragasso, G.; Scaglietti, U.; Pini, D.; Fortis, C.; Tresoldi, M.; Rugarli, C. Plasma nitrate plus nitrite changes during continuous intravenous infusion interleukin 2. Br. J. Cancer 1996, 74, 1297-1301.
110. Ogilvie, A. C.; Hack, C. E.; Wagstaff, J.; van Mierlo, G. J.; Erenberg, A. J.; Thomsen, L. L.; Hoekman, K.; Rankin, E. M. IL-1 beta does not cause neutrophil degranulation but does lead to 1L-6, 1L-8, and nitrite/nitrate release when used in patients with cancer. J. Immunol. 1996, 156, 389-394.
111. Moilanen, E.; Thomsen, L. L.; Miles, D. W.; Happerfield, D. W.; Knowles, R. G.; Moncada, S. Persistent induction of nitric oxide synthase in tumours from mice treated with the anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid. Br. J. Cancer 1998, 77, 426-433.
112. Baylis, C.; Vallance, P. Measurement of nitrite and nitrate levels in plasma and urine-what does this measure tell us about the activity of the endogenous nitric oxide system? Curr. Opin. Nephrol. Hypertension 1998, 7, 59-62.
113. Taylor, B. S.; de Vera, M. E.; Ganster, R. W.; Wang, Q.; Shapiro, R. A.; Morris, S. M. J.; Billiar, T. R.; Geller, D. A. Multiple NF-KappaB enhancer elements regulate cytokine induction of the human inducible nitric oxide synthase gene. J. Biol. Chem. 1998, 273, 15148-15156.
114. Geller, D. A.; Billiar, T. R. Molecular biology of nitric oxide syntheses. Cancer Metast. Rev. 1998, 17, 7-23.
115. Mellott, J. K.; Nick, H. S.; Waters, M. F.; Billiar, T. R.; Geller, D. A.; Chesrown, S. E. Cytokine-induced changes in chromatin structure and in vivo footprints in the inducible NOS promoter. Am. J. Physiol. Lung Cell Mol. Physiol. 2001, 250, L390-L399.
116. Dhawan, P.; Richmond, A. A novel NF-Kappa B-inducing kinase-MAPK signaling pathway up-regulates NF-Kappa B activity in melanoma cells. J. Biol. Chem. 2002, 277, 7920-7928.
117. Richmond, A. NF-Kappa B, Chemokine Gene Transcription and Tumour Growth. Nat. Rev. Immunol. 2002, 2, 664-674
118. Zheng, M.; Ekmekcioglu, S.; Walch, E. T.; Tang, C. H.; Grimm, E. A. Inhibition of nuclear factor-kappa b and nitric oxide by curcumin induces G2/M cell cycle arrest and apoptosis in human melanoma cells. Melanoma Res. 2004, 14, 165-171
119. Misko, T. P.; Trotter, J. L.; Cross, A. H. Mediation of inflammation by encephalitogenic cells: interferon [gamma] induction of nitric oxide synthase and cyclooxygenase 2. J. Neuroimmunol. 1995, 61, 195-204.
120. Tabatabaie, T.; Vasquez, A. M.; Moore, D. R.; Floyd, R. A.; Kotake, Y. Direct administration of interleukin-1 and interferon-gamma to rat pancreas leads to the in vivo production of nitric oxide and expression of inducible nitric oxide synthase and inducible cyclooxygenase. Pancreas 2001, 23, 316-322.
121. Yang, J.; Richmond, A. Constitutive IkappaB kinase activity correlates with nuclear factor-kappab activation in human melanoma cells. Cancer Res. 2001, 61, 4901-4909.
122. Feinstein, D. L.; Galea, E.; Aquino, D. A.; Li, G. C.; Xu, H.; Reis, D. J. Heat shock protein 70 suppresses astroglial-inducible nitric-oxide synthase expression by decreasing NFkappaB activation. J. Biol. Chem. 1996, 271, 17724-17732.
123. Demarco, V. G.; Scumpia, P. O.; Bosanquet, J. P.; Skimming, J. W. Alpha-lipoic acid inhibits endotoxin-stimulated expression of INOS and nitric oxide independent of the heat shock response in RAW 264.7 cells. Free Radic. Res. 2004, 38, 675-682.
124. Vallance, P.; Leiper, J. Blocking NO synthesis: How, where and why? Nat. Rev. Drug Discov. 2002, 1, 939-950.
125. Matter, H.; Kotsonis, P. Biology and chemistry of the inhibition of nitric oxide synthases by pteridine-derivatives as therapeutic agents. Med. Res. Rev. 2004, 24, 662-684.
126. Crowell, J. A.; Steele, V. E.; Sigman, C. C.; Fay, J. R. Is inducible nitric oxide synthase a target for chemoprevention? Mol. Cancer Ther. 2003, 2, 815-823.
127. Rees, D. D.; Palmer, R. M.; Hodson, H. F.; Moncada, S. A specific inhibitor of nitric oxide formation from 1-arginine attenuates endothelium-dependent relaxation. Br. J. Pharmacol. 1989, 96, 418-424.
128. Moore, P. K.; al Swayeh, O. A.; Chong, N. W.; Evans, R. A.; Gibson, A. L-NG-nitro arginine (L-NOARG), a novel, L-arginine-reversible inhibitor of endothelium-dependent vasodilatation in vitro. Br. J. Pharmacol. 1990, 99, 408-412.
129. Li, H.; Raman, C. S.; Glaser, C. B.; Blasko, E.; Young, T. A.; Parkinson, J. F.; Whitlow, M.; Poulos, T. L. Crystal structures of zinc-free and -bound heme domain of human inducible nitric-oxide synthase, implications for dimer stability and comparison with endothelial nitric-oxide synthase. J. Biol. Chem. 1999, 274, 21276-21284.
130. Rees, D. D.; Palmer, R. M.; Schulz, R.; Hudson, H. F., Moncada, S. Characterization of three inhibitors of endothelial nitric oxide synthase in vitro and in vivo. Br. J. Pharmacol. 1990, 101, 746-752.
131. Moore, W. M.; Webber, R. K., Jerome, G. M.; Tjoeng, F. S.; Misko, T. P.; Currie, M. G. L-N6-(1-iminoethyl)lysine: a selective inhibitor of inducible nitric oxide synthase. J. Med. Chem. 1994, 37, 3886-3888.
132. Garvey, E. P.; Oplinger, J. A.; Furfine, E. S.; Kiff, R. J.; Laszlo, F.; Whittle, B. J.; Knowles, R. G. 1400W is a slow, tight binding, and highly selective inhibitor of inducible nitric-oxide synthase in vitro and in vivo. J. Biol. Chem. 1997, 272, 4959-4963.
133. Young, R. J.; Beams, R. M.; Carter, K.; Clark, H. A. R.; Coe, D. M.; Chambers, C. L.; Davies, P. I.; Dawson, J.; Drysdale, M. J.; Franzman, K. W. Inhibition of inducible nitric oxide synthase by acetamidine derivatives of hetero-substituted lysine and homolysine. Bioorg. Med. Chem. Lett. 2000, 10, 597-600.
134. Blasko, E.; Glaser, C. B.; Devlin, J. J.; Xia, W.; Feldman, R. I.; Polokoff, M. A.; Phillips, G. B.; Whitlow, M.; Auld, D. S.; McMillan, K.; Ghosh, S.; Stuehr, D. J.; Parkinson, J. F. Mechanistic studies with potent and selective inducible nitricoxide synthase dimerization inhibitors. J. Biol. Chem. 2002, 277, 295-302.
135. Matter, H.; Kotsonis, P.; Klingler, O.; Strobel, H.; Frohlich, L. G.; Frey, A.; Pfleiderer, W.; Schmidt, H. H. Structural requirements for inhibition of the neuronal nitric oxide synthase (NOS-1): 3D-QSAR analysis of 4-oxo- and 4-amino-pteridine-based inhibitors. J. Med. Chem. 2002, 45, 2923-2941.
136. Surh, Y. J.; Chun, K. S.; Cha, H. H.; Han, S. S.; Keum, Y. S.; Park, K. K.; Lee, S. S. Molecular mechanisms underlying chemopreventive activities of anti-inflammatory phytochemicals: down-regulation of COX-2 and iNOS through suppression of NF-kappa B activation. Mutat. Res. 2001, 480-481, 243-268.
137. Timoshenko, A. V.; Lala, P. K.; Chakraborty, C. PGE2-mediated upregulation of INOS in murine breast cancer cells through the activation of EP4 receptors. Int. J. Cancer 2004, 108, 384-389.
138. Billard, C.; Kern, C.; Tang, R.; Ajchenbaum-Cymbalista, F.; Kolb, J. P. Flavopiridol downregulates the expression of both the inducible NO synthase and p27(Kip1) in malignant cells from B-cell chronic lymphocytic leukemia. Leukemia 2003, 17, 2435-2443.
139. Billard, C. H. R. I.; Quiney, C. L. A. I.; Tang, R. U. O. P.; Kern, C. A. T. H.; Ajchenbaum-Cymbalista, F. L. O. R.; Dauzonne, D. A. N. I.; Kolb, J. P. The inducible NO iynthase is downregulated during apoptosis of malignant cells from B-cell chronic lymphocytic leukemia induced by flavopiridol and polyphenols. Ann. NY Acad. Sci. 2003, 1010, 381-383.